Afrique du Sud - anglais - South African Health Products Regulatory Authority (SAHPRA)

msd (pty) ltd - capsules - see ingredients - each pack contains aprepitant a

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أداتكو - adatco drug store - aprepitant 1 cap (125mg) + 2 cap (80mg) - 1 cap (125mg) + 2 cap (80mg)

Union européenne - anglais - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosaprepitant - vomiting; cancer - antiemetics and antinauseants, - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.ivemend 150 mg is given as part of a combination therapy.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - aprepitant -

Canada - anglais - Health Canada

merck canada inc - aprepitant - capsule - 125mg - aprepitant 125mg - neurokinin-1 receptor antagonists

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - fosaprepitant dimeglumine, quantity: 257.6 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide; hydrochloric acid; polysorbate 80; lactose - emend iv, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy (see dosage and administration); - moderately emetogenic cancer chemotherapy (see dosage and administration).